Diet-associated vertically transferred metabolites and risk of asthma, allergy, eczema, and infections in early childhood

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Background: Evidence suggests maternal pregnancy dietary intake and nutrition in the early postnatal period to be of importance for the newborn child's health. However, studies investigating diet-related metabolites transferred from mother to child on disease risk in childhood are lacking. We sought to investigate the influence of vertically transferred metabolites on risk of atopic diseases and infections during preschool age. Methods: In the Danish population-based COPSAC2010 mother–child cohort, information on 10 diet-related vertically transferred metabolites from metabolomics profiles of dried blood spots (DBS) at age 2–3 days was analyzed in relation to the risk of childhood asthma, allergy, eczema, and infections using principal component and single metabolite analyses. Results: In 678 children with DBS measurements, a coffee-related metabolite profile reflected by principal component 1 was inversely associated with risk of asthma (odds ratio (95% CI) 0.78 (0.64; 0.95), p =.014) and eczema at age 6 years (0.79 (0.65; 0.97), p =.022). Furthermore, increasing stachydrine (fruit-related), 3-carboxy-4-methyl-5-propyl-2-furanpropanoate (fish-related), and ergothioneine (fruit-, green vegetables-, and fish-related) levels were all significantly associated with reduced risks of infections at age 0–3 years (p <.05). Conclusion: This study demonstrates associations between pregnancy diet-related vertically transferred metabolites measured in children in early life and risk of atopic diseases and infections in childhood. The specific metabolites associated with a reduced disease risk in children may contribute to the characterization of a healthy nutritional profile in pregnancy using a metabolomics-based unbiased tool for predicting childhood health.

OriginalsprogEngelsk
Artikelnummere13917
TidsskriftPediatric Allergy and Immunology
Vol/bind34
Udgave nummer2
Antal sider8
ISSN0905-6157
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
All funding received by COPSAC is listed on www.copsac.com . The Lundbeck Foundation (Grant no. R16‐A1694); The Ministry of Health (Grant no. 903516); Danish Council for Strategic Research (Grant no. 0603‐00280B); and The Capital Region Research Foundation have provided core support to the COPSAC research center. This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant no. 946228). NB received funding from the Capital Region Research Foundation (Grant no. A7187). JL‐S received funding from National Heart, Lung, and Blood Institute grants R01HL123915, R01HL141826, R01HL155742.

Publisher Copyright:
© 2023 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

ID: 358093886